Sonrotoclax Plus Zanubrutinib Generates Responses in Treatment-Naive CLL/SLL
Sonrotoclax plus zanubrutinib produced responses and was well tolerated in previously untreated chronic lymphocytic leukemia/small lymphocytic lymphoma.
Related Articles
The Rapidly Evolving Treatment Landscape in PIK3CA-mutated HR+ HER2- Breast Cancer
Panelists discuss how the evolving landscape of targeted therapies for PIK3CA-mutated HR+ HER2- breast cancer, including the approval of inavolisib and the growing importance of…
PRMT5-regulated splicing of DNA repair genes drives chemoresistance in breast cancer stem cells
Oncogene – PRMT5-regulated splicing of DNA repair genes drives chemoresistance in breast cancer stem cells
Thousands of women with breast cancer may not need ANY treatment
A breast cancer diagnosis is almost always followed by invasive biopsies, surgery, radiotherapy, chemotherapy and hormone treatments. But could all that be set to change?
Hairy Kidneys and Sclerotic Bone Lesions
A 72-year-old man with a history of polycythemia vera (positive for JAK2 V617F) presented with several months of functional decline and weight loss. An 18F-fluorodeoxyglucose…
3 QUESTIONS ON . . . The Impact of Historical Redlining on… : Oncology Times
An abstract is unavailable.
Maintenance Teclistamab With or Without Lenalidomide Is Safe, Active in Newly Diagnosed Myeloma
Maintenance therapy with teclistamab with or without lenalidomide was safe and efficacious in newly diagnosed multiple myeloma.
Oncological Safety of MRI-Informed Biopsy Decision-Making in Men With Suspected Prostate Cancer
This cohort study assesses the feasibility and safety of a community-based magnetic resonance imaging (MRI) diagnostic strategy in men with suspected prostate cancer using 3-year…
FDA Grants Breakthrough Therapy Designation to Dato-DXd for Previously Treated EGFR+ Advanced NSCLC
The FDA granted breakthrough therapy designation to Dato-DXd for previously treated EGFR-mutated advanced non–small cell lung cancer.
NFKB1 Haplotype Decreases Inflammation, Increases Response to Ropeginterferon Alfa-2b in PV and ET
NFKB1 rs230511 reduces inflammation and amplifies responses to ropeginterferon alfa-2b in polycythemia vera and essential thrombocythemia.
Phase II trial of durvalumab + lenalidomide vs single-agent durvalumab in refractory/advanced CTCL
Christiane Querfeld, MD, PhD, City of Hope, Duarte, CA, presents the results of a randomized Phase II trial (NCT03011814) investigating the safety and efficacy of…
